Ukraine on verge of new increase in drug prices

13 January 2015

Ukraine is on the verge of a new increase of pharmaceutical prices and a potential shortage of drugs, due to recently announced state plans to introduce an additional charge on drug imports to the country in the amount of 5%-10%.

It is expected that the new charge will help to attract additional revenue to the Ukrainian state budget. At the same time it is planned that it will not affect imports of vital drugs, reports The Pharma Letter’s local correspondent.

In the explanatory memorandum, the Ukrainian government said that the introduction of such import charges fully complies with World Trade Organization (WTO) rules, as the financial situation in Ukraine has significantly deteriorated for the last 12 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >